Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on marketable securities | NaN | 0 | 0 | 0 |
| Change in fair value of marketable securities | NaN | NaN | 0 | 0 |
| Accrued interest settled with common stock | NaN | 0 | 0 | 0 |
| Loss on settlement of convertible debt | NaN | 0 | 0 | 0 |
| Expense for debt issuance costs due to fair value election on convertible notes | NaN | 0 | NaN | NaN |
| Expense for issuance costs due to liability classified warrants | NaN | 0 | NaN | NaN |
| Loss on issuance of convertible notes - fair value option | NaN | 0 | NaN | NaN |
| Accrued interest income | NaN | 0 | 0 | 0 |
| Accounts payable and accrued expenses - related parties | NaN | 0 | 0 | 0 |
| Interest payments on convertible notes accounted for at fair value | 0 | -27,482 | -27,480 | -60,377 |
| Accrued interest payable | NaN | 0 | 0 | 0 |
| Change in fair value of convertible notes | 0 | -60,433 | -64,369 | 121,451 |
| Other assets | NaN | 0 | NaN | NaN |
| Accrued interest payable - related parties | 0 | 0 | -590 | -1,195 |
| Net loss | -2,152,471 | -2,614,895 | -2,347,302 | -6,759,472 |
| Depreciation | NaN | NaN | 1,008 | 29 |
| Depreciation and amortization | 633,340 | 290,107 | NaN | NaN |
| Change in fair value of derivative liabilities | 76,264 | -91,149 | 2,427 | 14,316 |
| Amortization of debt discount and finance fees | 12,122 | 13,921 | 18,182 | 29,927 |
| Gain on settlement of debt | NaN | -342,650 | NaN | NaN |
| Stock-based compensation | 35,018 | 214,750 | 134,318 | 583,899 |
| Prepaid expenses | NaN | -205,339 | NaN | 83,472 |
| Prepaid expenses and other current assets | 323,604 | NaN | 880,497 | NaN |
| Accounts payable and accrued expenses | 335,951 | -453,303 | 331,198 | 545,099 |
| Change in operating lease asset and liabilities | -904 | -904 | -905 | -650 |
| Impairment of right-of-use asset | NaN | 109,235 | NaN | NaN |
| Net cash used in operating activities | -2,417,309 | -973,012 | -2,626,654 | -5,881,979 |
| Investment in marketable securities | NaN | 0 | 0 | 0 |
| Proceeds from disposition of marketable securities | NaN | 0 | 0 | 0 |
| Investment in developed technology related to molecule.ai asset acquisition | NaN | 3,044,722 | NaN | NaN |
| Payment for issuance costs related to liability-classified warrants | NaN | 0 | NaN | NaN |
| Payments made for capitalized software | 36,000 | 12,000 | NaN | NaN |
| Payment of convertible note payable | NaN | 0 | 0 | 0 |
| Net cash used in investing activity | -36,000 | -3,056,722 | 0 | 0 |
| Proceeds from exercise of pre-funded warrants | NaN | NaN | NaN | 19,652 |
| Repayment of note payable-related party | 0 | 65,326 | NaN | 124,944 |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 322,051 | 0 | 1,329,673 | 0 | 4,080,000 |
| Proceeds from note payable-related party | NaN | 0 | NaN | NaN |
| Proceeds from exercise of pre-funded warrants | NaN | 349 | 19,802 | NaN |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 170,000 | NaN | 4,080,000 | NaN | NaN |
| Repayment of note payable-related party | NaN | NaN | -190,270 | NaN |
| Proceeds from convertible notes payable | NaN | 0 | NaN | NaN |
| Payment for finance costs | 0 | -4,262 | 0 | 78,414 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs of 235,514 | NaN | 2,264,485 | NaN | NaN |
| Proceeds from issuance of common stock and pre-funded warrants, net of placement agent costs of 275,000 | 3,225,000 | -5,409,673 | 0 | 5,409,673 |
| Payment of other issuance costs for issuance of common stock and equity-classified warrants | 15,750 | 0 | 31,199 | 526,460 |
| Net cash provided by financing activities | 3,209,250 | 2,269,096 | -96,375 | 8,779,507 |
| Net change in cash and cash equivalents | 755,941 | -1,760,638 | NaN | NaN |
| Net change in cash and cash equivalents | 755,941 | -1,760,638 | -2,723,029 | 2,897,528 |
| Cash and cash equivalents, beginning of period | 334,005 | 2,094,643 | 1,920,144 | NaN |
| Cash and cash equivalents, end of period | 1,089,946 | 334,005 | 2,094,643 | NaN |